Posts Tagged ‘Retina’
Exploring the Keys to Combination Therapies in Retina
The keys to developing combination therapies to treat retinal diseases lie in clinicians being able to better identify biomarkers for disease progression, developing strategies for staging disease, and finding a place for agents that act on disease pathways other than vascular endothelial growth factor, say ophthalmology leaders. Participants at a breakfast panel at OIS@AAO explored…
Read MoreNext Few Months Important for Clearside
The next few months will be important for Clearside Biomedical, one of the companies pioneering drug delivery to the suprachoroidal space. The company expects by the end of this month to receive topline data from its Phase II Dogwood trial that is evaluating safety and efficacy of CLS-TA in macular edema associated with non-infectious uveitis.…
Read MoreOpthea Taking New Approach to Combat Wet AMD
Megan Baldwin, PhD, Managing Director and CEO of Opthea, gives an update on OPT-302, a soluble receptor consisting of the first three extracellular domains of human VEGFR-3 linked to the Fc region of hIgG1. Baldwin explains how OPT-302 potently and specifically blocks VEGF-C and VEGF-D from binding and activating VEGFR-2 and VEGFR-3, making it a…
Read MoreDuker Sees “Energy” Being Added to Gene Therapy Field
Jay Duker, MD, Director of the New England Eye Center and Chairman of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine, tells OISTV the approval of gene therapy products including Spark Therapeutics’ SPK-RPE65 would help the sector clear a “real and psychological” hurdle facing gene therapy companies. Speaking With: Jay Duker,…
Read MoreAllegro Ophthalmics
Allegro Ophthalmics describes itself as a “mid-stage biotech company.” Its lead agent, Luminate, is an integrin peptide therapy that is the subject of a number of Phase II trials, including a trial that released topline data in September on its efficacy in vitreomacular traction. Other Phase IIb trials in progress are investigating Luminate for the…
Read MoreApplied Genetic Technologies Corporation (AGTC)
CEO Mark Shearman, MD, PhD, describes Applied Genetic Technologies Corp., known as AGTC, as a clinical-stage biotechnology company focused on developing its proprietary gene vector technology for treatment of orphan monogenic diseases of the retina. AGTC signed an R&D partnership with Biogen to oversee biological development and commercialization of its platform, which Dr. Shearman described…
Read MoreVision Medicines
Vision Medicines is working on developing two agents for the treatment of ocular diseases: VM100 for treatment of geographic atrophy and intermediate age-related macular degeneration (AMD), and VM200 for treatment of Stargardt disease. VM100 is a monoclonal antibody whose mechanism of action is to clear retinal amyloid (A beta) and its complement. VM100 can be…
Read MoreInotek Pharmaceuticals
David P. Southwell, president and CEO of Inotek Pharmaceuticals, spelled out the focus of his clinical-stage biopharmaceutical firm in no uncertain terms at OIS@AAO. “Inotek is focused on glaucoma,” he said. “Clearly the optimal eyedrop to treat glaucoma would be one that both lowers intraocular pressure (IOP) in a well-tolerated fashion and is also neuroprotective.”…
Read MoreTranslatum Medicus
Presenter: Shelley Boyd, MD, FRCSC Shelley Boyd, MD, FRCSC, is an Ophthalmologist specializing in diseases of the retina and founding President & CSO of Translatum Medicus Inc(TMi). She trained at the University of Toronto, with fellowships at Moorfields Eye Hospital, UK and the Scripps Research Institute, California. View Full Profile
Read MoreOcata Therapeutics
Ocata Therapeutics, which has trademarked the term Regenerative Ophthalmology, is developing stem cell therapies for Stargardt macular degeneration, dry age-related macular degeneration (AMD), and myopic macular degeneration, Chief Medical Officer Eddy Anglade, MD, reported at OIS@AAO. The company’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) –…
Read MoreCircadian Technologies (Opthea)
Participant: Megan Baldwin Dr. Megan Baldwin is CEO/Managing Director of Circadian Technologies (Opthea) and has over 19 years of experience in preclinical and clinical development of therapies for cancer and eye diseases. View Full Profile
Read MoreIconic Therapeutics
Participant: William L. Greene, MD Dr. Greene has served as CEO of Iconic Therapeutics since 2014. He brings 20 years of experience as an operating executive, clinician, investor, and entrepreneur. View Full Profile
Read More